Colcrys is a brand name of colchicine, approved by the FDA in the following formulation(s):
COLCRYS (colchicine - tablet; oral)
Manufacturer: AR HOLDING CO INC
Approval date: July 29, 2009
Strength(s): 0.6MG [RLD]
Has a generic version of Colcrys been approved?
No. There is currently no therapeutically equivalent version of Colcrys available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Colcrys. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Methods for concomitant administration of colchicine and macrolide antibiotics in the treatment of gout flares
Patent 7,601,758
Issued: October 13, 2009
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for treating gout flares comprising concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.Patent expiration dates:
- February 10, 2029✓
- February 10, 2029
Methods for concomitant administration of colchicine and macrolide antibiotics
Patent 7,619,004
Issued: November 17, 2009
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin or erythromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for co-administration of colchicine together with macrolide antibiotics are also provided.Patent expiration dates:
- December 3, 2028✓
- December 3, 2028
Methods for concomitant administration of colchicine and a second active agent
Patent 7,820,681
Issued: October 26, 2010
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Patent expiration dates:
- February 17, 2029✓
- February 17, 2029
Methods for concomitant administration of colchicine and a second active agent
Patent 7,906,519
Issued: March 15, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): AR Holding Company, Inc.
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Patent expiration dates:
- February 17, 2029✓
- February 17, 2029
Methods for concomitant administration of colchicine and a second active agent
Patent 7,915,269
Issued: March 29, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): AR Holding Company, Inc.
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Patent expiration dates:
- February 17, 2029✓
- February 17, 2029
Methods for concomitant administration of colchicine and macrolide antibiotics
Patent 7,935,731
Issued: May 3, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.Patent expiration dates:
- December 3, 2028✓
- December 3, 2028
Colchicine compositions and methods
Patent 7,964,647
Issued: June 21, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Patent expiration dates:
- October 6, 2028✓
- October 6, 2028
Methods for concomitant administration of colchicine and a second active agent
Patent 7,964,648
Issued: June 21, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Patent expiration dates:
- October 6, 2028✓
- October 6, 2028
Colchicine compositions and methods
Patent 7,981,938
Issued: July 19, 2011
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.Patent expiration dates:
- October 6, 2028✓
- October 6, 2028
Methods for concomitant administration of colchicine and macrolide antibiotics
Patent 8,093,296
Issued: January 10, 2012
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.Patent expiration dates:
- October 6, 2028✓
- October 6, 2028
Methods for concomitant administration of colchicine and a second active agent
Patent 8,093,297
Issued: January 10, 2012
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.Patent expiration dates:
- October 6, 2028✓
- October 6, 2028
Methods for concomitant administration of colchicine and macrolide antibiotics
Patent 8,093,298
Issued: January 10, 2012
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.Patent expiration dates:
- October 6, 2028✓
- October 6, 2028
Methods for concomitant administration of colchicine and macrolide antibiotics
Patent 8,097,655
Issued: January 17, 2012
Inventor(s): Davis; Matthew W.
Assignee(s): Mutual Pharmaceutical Company, Inc.
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.Patent expiration dates:
- October 6, 2028✓
- October 6, 2028
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- July 30, 2012 - GOUT FLARES
- July 29, 2016 - ORPHAN DRUG EXCLUSIVITY
See also...
- Colcrys Consumer Information (Drugs.com)
- Colcrys Consumer Information (Wolters Kluwer)
- Colcrys Consumer Information (Cerner Multum)
- Colcrys Advanced Consumer Information (Micromedex)
- Colcrys AHFS DI Monographs (ASHP)
- Colchicine Consumer Information (Wolters Kluwer)
- Colchicine Consumer Information (Cerner Multum)
- Colsalide Advanced Consumer Information (Micromedex)
- Colchicine Oral, Intravenous Advanced Consumer Information (Micromedex)
- Colchicine AHFS DI Monographs (ASHP)
